Myeloproliferative neoplasms (MPN) are a rare form of blood cancer. Though most people don’t know a lot about, approximately 20,000 people develop MPNs each year. Here are the basics you can explain to a concerned patient.
A review of 2 pivotal clinical trials describes the efficacy and safety of fedratinib in patients with myeloproliferative neoplasm-associated myelofibrosis.
A systematic review of published studies compared effectiveness of antiplatelet and anticoagulant therapies — alone, combined, and with cytoreduction — in reducing thrombotic events in this population.
Observational, retrospective study revealed factors that may be linked to higher mortality risk in patients with MPN and COVID-19.
Researchers determined the impact of mutations in the CALR gene on thrombotic risk for patients with essential thrombocythemia.